Dexferrum

(Iron dextran)

ApprovedSmall molecule

NNew River Pharmaceuticals

Dexferrum is one of 109 small molecule programs targeting Iron deficiency anemia. It is currently in Approved.

Indications

Total Trials

Active Trials

108

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Iron Deficiency AnemiaActive, not recruiting

HypophosphatemiaActive, not recruiting

AnemiaActive, not recruiting

Acute Kidney InjuryActive, not recruiting

Iron Deficiency AnemiaPhase 3

Active, not recruiting

HypophosphatemiaPhase 2

Active, not recruiting

AnemiaApproved

Active, not recruiting

Acute Kidney InjuryPhase 2

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Anemia

#DrugCompanyPhaseTrials

Dexferrum

NNew River Pharmaceuticals

Approved

2 2

Soliris

AstraZeneca

Phase 3

1 3

Ultomiris

AstraZeneca

Phase 3

1 4

LNP023

Novartis

Phase 3

1 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

52 6

Aranesp

Amgen

Preclinical

38 7

ERYPO, Janssen-Cilag

Novartis

Phase 3

2 8

Ferumoxytol or Oral Iron

AAMAG Pharmaceuticals, Inc.

Phase 3

1 9

Eprex

SShenyang Sunshine Pharmaceutical Co., LTD.

Phase 3

1 10

Recombinant Human Erythropoietin Alpha

CCadila Pharnmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Iron deficiency anemia2 trials

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia

Completed·AAmerican Regent, Inc.·Phase 3·NCT00704028·161 enrolled

Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women

Completed·—·Phase 3·NCT03212781·66 enrolled

Anemia2 trials

Practical Anemia Bundle for SusTained Blood Recovery

Completed·MMayo Clinic·Phase 2·NCT05167734·100 enrolled

Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

Completed·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT05047211·40 enrolled

Acute Kidney Injury1 trial

Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury

Completed·HHospital Civil de Guadalajara·Phase 2·NCT05960227·120 enrolled

Iron-deficiency1 trial

Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality

Completed·—·N/A·NCT02889133·79 enrolled

Pregnancy1 trial

Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Completed·IIndiana University·Phase 4·NCT03438227·38 enrolled

3 more indications

Intravenous1 trial

Trial Comparing the Safety of Two Different Intravenous Iron Formulations

Suspended·LLondon Health Sciences Centre·Phase 4·NCT00593619·200 enrolled

Children1 trial

Comparative Study Between Oral Liposomal Iron,Iron Supported Lactoferrin and IV Iron Dextran in CKD Children

Unknown status·MMenoufia University·Phase 4·NCT05714176·90 enrolled

Hypophosphatemia1 trial

Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding

Completed·AAmerican Regent, Inc.·Phase 2·NCT01307007·69 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

INFED

NDA NDA017441

Jan 1, 1982

IRON DEXTRAN

NDA NDA010787

Jan 1, 1982

PROFERDEX

NDA NDA017807

Feb 23, 1996

DEXFERRUM

NDA NDA040024

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Iron dextran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iron dextran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iron dextran. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA040024). U.S. Food & Drug Administration.
[5]
SEC EDGAR — New River Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNew River Pharmaceuticals

Dexferrum

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Iron deficiency anemia2 trials

Anemia2 trials

Acute Kidney Injury1 trial

Iron-deficiency1 trial

Pregnancy1 trial

Intravenous1 trial

Children1 trial

Hypophosphatemia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News